chlorpromazine; haloperidol; neuroleptic agent; olanzapine; aggression; article; clinical decision making; coronavirus disease 2019; data analysis; data visualization; dementia; disease severity; drug cost; drug manufacture; drug mechanism; government; health care cost; health service; human; incidence; investment; law; maintenance therapy; mental disease; mental health; mental health service; pandemic; personality disorder; prescription; prevalence; price; psychosis; psychosocial intervention; reimbursement; schizophrenia; symptom; treatment indication; United Kingdom; violence